Premium
Preformulation study of the vaccine candidate TAB9 against HIV‐1
Author(s) -
Raya Néstor Expósito,
Díaz Alina García,
López Yamilka Carrazana,
Vazquez Diógenes Quintana,
Díaz Dagmara Pichardo,
Puente Nieves Martínez de la,
Cano Carlos Duarte
Publication year - 2002
Publication title -
biotechnology and applied biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 70
eISSN - 1470-8744
pISSN - 0885-4513
DOI - 10.1042/ba20020048
Subject(s) - immunogenicity , adjuvant , aluminium hydroxide , adsorption , chromatography , human immunodeficiency virus (hiv) , chemistry , aluminium , biology , virology , immunology , antibody , organic chemistry
A preformulation study was performed for the evaluation of a vaccine candidate against HIV‐1. Aluminium hydroxide was used in the preformulation. However, this adjuvant is not a good adsorbent for basic proteins since it is positively charged at a physiological pH. In the present study, we determined the adsorption of TAB9 (basic protein, pI: 11.3) by treating Alhydrogel with different ions. The immunogenicity of the vaccine candidate against HIV was also evaluated using three batches, 9801‐A, 9802‐A and 9803‐A, and a placebo P‐001. The evaluation was performed twice (0 and 9 months). Each batch was tested using groups of 10 mice that had a single inoculation. The results showed that the protein was totally adsorbed to the aluminium gel. Seroconvertion was attained in all analysed batches, indicating the potentiality of TAB9 as a vaccine candidate.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom